替吉奥联合卡培他滨治疗晚期转移性胰腺癌的疗效观察  

Efficacy of tegafur combined with capecitabine in the treatment of advanced metastatic pancreatic cancer

作　　者：刘恩萍[1] 王静[1] 窦乐功[1] LIU En-ping WANG Jing DOU Le-gong(Department of Internal Medicine, Linqu County People＇s Hospital, Linqu 262600, Chin)

机构地区：[1]山东省临朐县人民医院内科,临朐262600

出　　处：《中国肿瘤临床与康复》2017年第5期590-592,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨替吉奥联合卡培他滨治疗晚期转移性胰腺癌的临床疗效。方法选取2013年1月至2016年1月间山东省临朐县人民医院收治的50例晚期胰腺癌患者,按照治疗方式不同分为观察组与对照组,每组25例。观察组采用替吉奥联合卡培他滨治疗,对照组采用卡培他滨治疗,观察两组患者治疗效果及安全性。结果观察组患者治疗有效率和疾病控制率分别为48.0%和80.0%,对照组患者分别为20.0%和40.0%,差异均有统计学意义(均P<0.05)。两组患者6个月生存率分别为67.9%和60.5%,1年生存率分别为31.3%和26.5%,中位生存时间分别为9.2个月和8.1个月,差异均无统计学意义(均P>0.05)。观察组患者粒细胞减少率和恶心呕吐发生率分别为36.0%和32.0%,均高于对照组患者的12.0%和8.0%,差异均有统计学意义(均P<0.05);两组患者腹泻、贫血、肝功能损伤和周围神经病变等不良反应发生率的比较,差异均无统计学意义(均P>0.05)。结论替吉奥联合卡培他滨治疗晚期转移性胰腺癌短期疗效较优,有延长生存时间趋势,不良反应可耐受、安全性较高,值得临床推广。Objective To investigate the efficacy of tegafur combined with capecitabine in the treatment of advanced metastatic pancreatic cancer. Methods Fifty patients with advanced pancreatic cancer treated at Linqu County People＇s Hospital from January 2013 to January 2016 wereselected. The pa- tients are divided into an observation group and a control group according to the therapy, with 25 patients in each group. The observation group was treated with tegafur combined with eapecitabine and the control group was treated with capecitabine. The therapeutic efficacy and safety were observed in the two groups. Results The efficacy and control rate was 43.0% and 80. 0%, respectively for the observation group and 20.0% and 40. 0% , respectively for the control group （P 〈 0.05 ）. The 6-month survival rates were 67. 9% and 60. 5%, 1-year survival rates were 31.3% and 26. 5% and overall median survival time was 9. 2 months and 8.1 months, respectively for the observation group and the control group （ all P 〉 0.05 ）. The incidence of neutropenia and nausea and vomiting were higher in the the observation group （36. 0% and 32. 0%, re- spectively） than in the control group （ 12.0% and 8.0% ） （P 〈 0.05 ）. There was no statistically signifi- cant difference in the incidence of side effects including diarrhea, anemia, liver damage and peripheral neu- ropathy between the two groups （P 〉 0. 05）. Conclusion Tegafur combined with capecitabine in the treat- ment of advanced metastatic pancreatic cancer has good efficacy, which may prolong the survival time with high safety and tolerable side effects and is worthy of promotion and application.

关 键 词：替吉奥 卡培他滨 胰腺肿瘤 

分 类 号：R735.9[医药卫生—肿瘤]